Back to search
FDAFDA · Food and drugs·Recall number D-0052-2027

Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.

Published October 28, 2026 · Recall initiated: September 29, 2026

Summary

FDA records drug Class II recall D-0052-2027, published October 28, 2026 and initiated September 29, 2026. Recalling firm: Pfizer; Status: Ongoing; Reported quantity: 15,815 100-count bottles; Lot: Lot # 24W06, Exp: 11/30/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email if LEVOXYL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LEVOXYL
Manufacturer
Pfizer
Distributor
US Nationwide and Puerto Rico
UPC
0360793858012
Lot
Lot # 24W06, Exp: 11/30/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01. recalled?

Yes. FDA published recall D-0052-2027 on October 28, 2026. Reported hazard: Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LEVOXYL. UPC: 0360793858012.